AACR 2019: Gilteritinib improved survival for patients with acute myeloid leukaemia
Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory…
Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory…
Kevin Pollock, Glasgow Caledonian University Cervical cancer is the third most common cancer among women…
Blood platelets which interact with liver cells and immune cells play a major role in…
The advent of immune checkpoint inhibitors – which “release the brakes” of the body’s immune…
The difficulty in spotting minute amounts of disease circulating in the bloodstream has proven a…
Starting routine colorectal cancer screening at age 45 rather than 50 would decrease U.S. cancer…
Devising the best treatment for a patient with cancer requires doctors to know something about…
Painful sores in the mouth and throat are one of the most common adverse side…
The Royal Australian and New Zealand College of Radiologists (RANZCR) applauds Opposition Leader Bill Shorten’s…
Researchers have observed for several years that people who have a history of using oral…